Edwards Lifesciences (NYSE:EW) Research Coverage Started at UBS Group

Posted by Francis Steltz on Jul 31st, 2026

UBS Group assumed coverage on shares of Edwards Lifesciences (NYSE:EW – Free Report) in a report issued on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $110.00 target price on the medical research company’s stock.

A number of other research firms also recently commented on EW. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research report on Wednesday, April 1st. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Truist Financial lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $100.27.

Read Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Trading Up 1.4%

Shares of EW opened at $87.00 on Tuesday. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $96.29. The stock has a market cap of $50.10 billion, a PE ratio of 50.00, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86. The firm’s fifty day moving average is $87.91 and its two-hundred day moving average is $83.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts forecast that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 44,558 shares of company stock valued at $3,770,939 over the last 90 days. 0.31% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after acquiring an additional 23,514 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $2,984,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $803,686,000. TD Asset Management Inc lifted its position in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after purchasing an additional 47,051 shares in the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock worth $5,912,000 after purchasing an additional 12,591 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.